8 minutes ago 0 shares Done LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. ( CBST ) today announced that the European Medicines Agency (EMA) has accepted for review the Companys Marketing Authorization Application (MAA) for its investigational antibiotic ceftolozane/tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections, with a decision from the European Commission (EC) expected during the second half of 2015. The MAA submission is based on positive data from two pivotal Phase 3 clinical trials of ceftolozane/tazobactam in complicated urinary tract infections and complicated intra-abdominal infections. These studies met both the EMA and U.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cubist-announces-ema-acceptance-ceftolozane-113000959.html
Custirsen has fast track designation in the U.S. for the treatment of advanced or metastatic NSCLC. We expect investor focus to remain on further updates from the company on custirsen. Meanwhile, OncoGenex is evaluating apatorsen in seven phase II studies for four types of cancer bladder, lung, pancreatic and prostate cancer. Results from the Borealis-1 study (metastatic bladder cancer) should be out in the first quarter of 2015. OncoGenex carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Endo International plc ( ENDP ) and United Therapeutics Corp.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/oncogenexs-custirsen-passes-first-interim-204002930.html
Pharma EXPO Debut Will Advance Innovation and Education for Pharmaceutical Professionals
The smooth, rounded and highly polished exterior of the robot has no external screws decreasing the potential for dust, dirt or other contaminant build up. The VS-050 has an ISO 5 cleanroom rating and has nickel plated aluminum coverings and sealed joints that allow it to be safely sterilized with hydrogen peroxide of UV light. The electrical wires and air lines are housed internally, further streamlining the robot arm and enabling faster clean-down operations. New 2-D Barcode Works With or Without Internet Access The patented HD Barcode from Complete Inspection Systems (Booth #N-5804) can store up to 175 times more data than traditional 2-D codes. Using a proprietary reading application, an authorized user can scan, read and verify product details from any location. Manufacturers can include track and trace information, product specifications, e-pedigree data, plant location, manufacture date, distribution region(s), package, carton or label identifiers, user data, full color images and marketing incentives. Point-of-Use System Exergy (Booth #W-562) will showcase its new Point-of-Use systems at Pharma EXPO 2014. The systems dispense instant, temperature controlled water for injection (WFI) or purified water (PW) and are designed to meet the high quality requirements and hygienic standards of the pharmaceutical industry. When not in use, a continuous flow of hot water from the main loop enhances the sanitization process. Exergy offers customers standard and customized models equipped with compact, high performance heat exchangers.
For the original version including any supplementary images or video, visit http://www.pharmaceuticalonline.com/doc/pharma-expo-debut-will-advance-innovation-and-education-for-pharmaceutical-professionals-0001?atc~c=771+s=773+r=001+l=a
5 companies that will get a boost from Ice Bucket Challenge | New York Post
In 2013, Isis reported positive safety data from the test, which represents a novel approach to ALS treatment by shutting off the mutated gene that causes the disease. Also last quarter, Isis senior vice president of research, Frank Bennett, was awarded the Commitment to a Cure Award by the ALS Association for the companys commitment to the disease. Sanofi had the only single medicine approved by the U.S. Food and Drug Administration to treat ALS. The drug, Rilutek, is proven to extend survival in patients with ALS. However, it was sold to Swiss-based Covis Pharma Sarl in 2013. Sanofi reported strong earnings for the second quarter in July, led by its rare disease and diabetes categories. Its shares are up 4 percent this month, though they are flat on the year. Bristol-Meyers Squibb has a large program dedicated to immune modulation, which could provide future opportunities for ALS therapeutics.
For the original version including any supplementary images or video, visit http://nypost.com/2014/08/22/5-companies-that-will-get-a-boost-from-ice-bucket-challenge/